KEITH STEELE,SONG WU,BRANDON HIGGS,MORITZ WIDMAIER,SONJA ALTHAMMER,RENE KORN,ANDREAS SPITZMUELLER
申请号：
US16346268
公开号：
US20190256603A1
申请日:
2017.11.10
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of durvalumab (MEDI4736) or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof. A combination of durvalumab and tremelimumab was effective at treating non-small cell lung cancers characterized as PD-L1- and having a high level of CD8+ tumor-infiltrating lymphocytes.
